It has been reported that up to 30% of CLL patients belong to B cell receptor (BCR) stereotypy and with “some” subsets conferring specific clinical outcomes, especially those who belong to subset#2 characterized with IGHV3‐21 usage and predominantly mutated IGHV status.11, 19, 20 Lacking the CDR3 information in 131 patients limited further identification of subsets. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.